Fig. 1 · Structure

Documents & Downloads

Astragaloside III

Cat. No. A12218 CAS 84687-42-3
Astragaloside I, II, III, and IV concentration-dependently increased the CD45-mediated of pNPP/OMFP hydrolysis with the EC50 values ranged from 3.33 to 10.42 ug/mL.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Astragaloside III Research Summary

This section summarizes 4 in vitro studies of Astragaloside III from 2 published references. In vitro models include WB-F344 cells; sodium butyrate-induced WB-F344 cell model.

Astragaloside III In Vitro Studies

Astragaloside III-stimulated NK cells decreased CFSE-labeled CT26 mean fluorescence intensity more than unstimulated NK cells during coculture. In WB-F344 cells, Astragaloside III did not significantly inhibit viability at concentrations up to 12.5 µM. In BALB/c mouse splenocytes with IL-2 and IL-12 present, Astragaloside III stimulation significantly increased NKG2D and IFN-γ expression on NK cells compared with control. In sodium butyrate-induced WB-F344 cells, Astragaloside III significantly decreased elevated CK19 mRNA expression compared with the sodium butyrate model group. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

NK cell coculture and CT26 fluorescence

Cell-based study · isolated NK cells; CFSE labeled tumor cells; CT26 [1]

CFSE-labeled CT26 tumor cells were cocultured with isolated NK cells stimulated by Astragaloside III. CT26 mean fluorescence intensity decreased more with stimulated NK cells than with unstimulated NK cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mean fluoresce intensity (MFI) of CFSE-labeled CT26Reported result mean fluoresce intensity (MFI) of CFSE-labeled CT26 (red line, 137) was decreased when the cells were co-cultured with unstimulated NK cells (blue line, 38.4), and more drastically decreased with NK cells stimulated by Astragaloside III (20 nM) (yellow line, 17)[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 nM
Exposure duration
After 6 h
Method
cocultured
Co-treatment
Other interventions in this design: isolated NK cells; CT26 E:T = 1:1. Compound effect isolated by the comparison: CT26 unstimulated NK cells (blue line) and CT26+NK cells +Astragaloside III (yellow line).
Reported limits
Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: Astragaloside III

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > NK Cells Stimulation and Coculture Experiments (S14, S15, S16); Results > Astragaloside III Induced CT26 Cell Death by Activating NK Cells (S49); Figure 2 legend (S99)

mean fluoresce intensity (MFI) of CFSE-labeled CT26: mean fluoresce intensity (MFI) of CFSE-labeled CT26; comparator: CT26 unstimulated NK cells (blue line) — Materials and Methods > NK Cells Stimulation and Coculture Experiments (S15); Results > Astragaloside III Induced CT26 Cell Death by Activating NK Cells (S49)

Cell Viability in WB-F344 Cells

Cell-based study · WB-F344 cells [2]

WB-F344 cells were incubated with Astragaloside III, and viability was evaluated by CCK8 assay. Cell viability was not significantly inhibited at concentrations up to 12.5 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability is evaluated by CCK8 assayReported result cell viability is not significantly inhibited within 12.5 µM of these compound[2]

Literature-Reported Treatment Conditions

Treatment concentration
6.25, 12.5, 25, 50 and 100 μM
Exposure duration
for 24 h
Method
incubated with
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Astragaloside III

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > The inhibitory effects of the main chemical constituents of ASTs on ductular reaction in sodium butyrate-induced WB-F344 cell model (S38, S39, S40, S41); Results > Effects of main chemical constituents of ASTs on SB-induced WB-F344 cell model (S106, S107)

cell viability is evaluated by CCK8 assay: cell viability is evaluated by CCK8 assay; comparator: control group — Results > Effects of main chemical constituents of ASTs on SB-induced WB-F344 cell model (S106, S107)

NK Cell Expression Responses in Mouse Spleenocytes

Cell-based study · Spleenocytes from BALB/c mice; CD49b+ CD3- [1]

Spleenocytes from BALB/c mice received Astragaloside III with IL-2 and IL-12 co-interventions. Compared with control, NKG2D and IFN-γ expression on NK cells increased significantly in the 20 nM and 40 nM stimulation groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
frequencies of IFN- γ (C) and NKG2D (D) expression on NK cellsReported result the increase of NKG2D and IFN-γ was significant in 20 nM and 40 nM stimulation groups, compared with control[1]

Literature-Reported Treatment Conditions

Treatment concentration
4, 12, 20, 40 nM
Exposure duration
After 48 h
Method
added
Co-treatment
Other interventions in this design: IL-2 2 ng/ml; IL-12 20 ng/ml. Compound effect isolated by the comparison: compared with control.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Astragaloside III

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > NK Cells Stimulation and Coculture Experiments (S11, S12, S13); Materials and Methods > Tumor Mouse Model and Treatment (S23); Results > Astragaloside III Elevated the Expression of NKG2D and IFN-γ in NK Cells in Vitro (S43, S45); Figure 1 legend (S96); Figure 2 legend (S100)

frequencies of IFN- γ (C) and NKG2D (D) expression on NK cells: frequencies of IFN- γ (C) and NKG2D (D) expression on NK cells; comparator: control — Results > Astragaloside III Elevated the Expression of NKG2D and IFN-γ in NK Cells in Vitro (S45); Figure 1 legend (S96)

CK19 Expression in Sodium Butyrate-Induced WB-F344 Cells

Cell-based study · sodium butyrate-induced WB-F344 cell model [2]

Sodium butyrate-induced WB-F344 cells received Astragaloside III at 10 µM in drug-containing medium. Compared with the sodium butyrate model group, elevated CK19 mRNA expression was significantly decreased.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Expression of CK19 is determined by qRT-PCRReported result The elevated mRNA expression of CK19 in SB-induced WB-F344 cell is significantly decreased in these compounds (10 µM) and ASTs groups (10 μg/ml) (p < 0.01)[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
Drug-containing medium and fresh medium are replaced after 2 days. All cells are maintained for 4 days
Method
Drug-containing medium
Co-treatment
Other interventions in this design: SB 3.75 µM. Compound effect isolated by the comparison: vs. SB model group.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Astragaloside III

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > The inhibitory effects of the main chemical constituents of ASTs on ductular reaction in sodium butyrate-induced WB-F344 cell model (S43, S45, S46, S47); Results > Effects of main chemical constituents of ASTs on SB-induced WB-F344 cell model (S109); FIGURE 5 legend (S137)

Expression of CK19 is determined by qRT-PCR: Expression of CK19 is determined by qRT-PCR; comparator: SB (3.75 µM) group — Results > Effects of main chemical constituents of ASTs on SB-induced WB-F344 cell model (S109); FIGURE 5 legend (S137)

Specifications

Manufacturer Adooq Bioscience
CAS Number 84687-42-3
Formula C41H68O14
Molecular Weight 784.97
SMILES
C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O)C)O)C)O)(C)C)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Astragaloside III Research References

  1. [1] Chen X, Chen X, Gao J, et al. Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ. Front Pharmacol (2019). PMID: 31456687 DOI: 10.3389/fphar.2019.00898 Source material
  2. [2] Zhang L, Hu Y, Qi S, et al. Astragalus saponins and its main constituents ameliorate ductular reaction and liver fibrosis in a mouse model of DDC-induced cholestatic liver disease. Front Pharmacol (2022). PMID: 36339578 DOI: 10.3389/fphar.2022.965914 Source material

Added to your cart

View Cart Checkout
Loading...